Send to

Choose Destination
Transl Lung Cancer Res. 2018 Apr;7(Suppl 2):S127-S130. doi: 10.21037/tlcr.2018.03.06.

First line osimertinib for the treatment of patients with advanced EGFR-mutant NSCLC.

Author information

Department of Medical Oncology, Santa Maria della Misericordia Hospital, University of Perugia, Perugia, Italy.

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center